Fig. 4: JNK-IN-8-expanded HSCs repopulate secondary recipients.

a Secondary engraftment in mouse recipients’ PB 21 weeks after transplantation of 1 × 10⁷ cells from BM of the primary recipients injected with DMSO or J8-expanded 10,000 day 0 CD34⁺ cells 21 weeks after transplantation. (n = 10 mouse from two independent experiments per group, *p = 0.0418 by two-tailed unpaired t test.) b HSC frequency in secondary recipient of J8 or DMSO-expanded cells calculated by ELDA software. More than 1% human CD45 engraftment in the BM was regarded as positive. As for overall test for differences in stem cell frequencies between any of the groups, p = 0.0251. c HSC frequencies presented as 1/fresh CD34⁺ cells equivalent for each condition from (b), the required confidence interval was 95%. More than 1% human CD45 engraftment in the BM was regarded as positive. See also Supplementary Table S3B. All data shown as mean values ± SD. Statistical significance was assessed using unpaired t test, where *p < 0.05